The Medicare Drug-Price Negotiation Playbook

Each year CMS publishes a list of the highest total Medicare Part D (and now Part B) spending drugs that meet the eligibility window — small molecules 9+ years past approval, biologics 13+ years past approval, no generic or biosimilar on the market yet. Manufacturers negotiate (under threat of a steep excise tax for non-participation) and CMS publishes a "maximum fair price" that takes effect roughly two years after the drug is selected. The first 10 drugs — including Eliquis (Bristol-Myers Squibb, ticker BMY, co-marketed with Pfizer, PFE), Jardiance and Ozempic-class rival Trajenta (Boehringer Ingelheim, private), Xarelto (Johnson & Johnson, JNJ), Januvia (Merck, MRK), Farxiga (AstraZeneca, ADR AZN), Enbrel (Amgen, AMGN), Stelara (J&J), Novolog-family insulins (Novo Nordisk, NVO), and Imbruvica (AbbVie, ABBV, with Johnson & Johnson) — saw negotiated prices take effect January 1, 2026.

The second batch of 15 drugs, selected in 2025 for 2027 pricing, leans harder into GLP-1s and oncology, again pulling in names like Novo Nordisk (NVO), Eli Lilly (LLY, via Jardiance's diabetes-class peers and other agents), and Johnson & Johnson (JNJ). The durable pattern: it is always the same handful of large-cap pharma names cycling through, because they are the ones with old, high-revenue, still-patent-protected drugs. That predictability is the tradeable part — you can look up next year's candidate list months before prices are finalized.

The losers are large-cap pharma manufacturers with a small number of aging blockbusters that make up an outsized share of total revenue and that skew heavily toward Medicare-age patients (diabetes, cardiovascular, autoimmune, oncology). Bristol-Myers Squibb (BMY) is a clean example: Eliquis was one of its largest single products and one of the first 10 negotiated drugs. AbbVie (ABBV) leaned on Imbruvica and faces continued exposure as its post-Humira portfolio ages into the eligibility window. Johnson & Johnson (JNJ), Merck (MRK), AstraZeneca (AZN), Novo Nordisk (NVO), and Amgen (AMGN) all had first- or second-round drugs selected and will keep cycling through as their own pipelines age.

The read-through isn't "short big pharma" — it's that revenue concentration is the risk factor, not sector membership. A company whose top 2-3 drugs are all old, Medicare-heavy, and still exclusive carries more negotiation risk per dollar of revenue than a diversified major with a broad, newer portfolio. Screening for revenue concentration in aging, single-source drugs — and checking whether a name's biggest sellers are within a few years of the 9-/13-year eligibility threshold — is a more durable diagnostic than reacting to any single year's CMS list.

Generic and biosimilar manufacturers benefit from the entire ecosystem this policy reinforces, since the program's core incentive is to accelerate the shift from originator drugs to lower-cost copies once patents lapse — and it explicitly exempts drugs once biosimilar/generic competition exists. Viatris (VTRM legacy ticker now VTRS) and Teva Pharmaceutical (TEVA) sit in the generics lane; biosimilar-focused players and CDMO-adjacent names benefit from the same structural push toward genericization, independent of any single year's negotiated list.

Companies whose flagship products are newer, or priced mostly through commercial insurance and cash-pay channels rather than Medicare, are largely untouched. Eli Lilly's (LLY) GLP-1 franchise (Mounjaro/Zepbound) is young enough to sit outside the eligibility window for years, even as Novo Nordisk's (NVO) older insulin lines get pulled in — a useful illustration that "same therapeutic class" does not mean "same policy exposure." Vertex Pharmaceuticals (VRTX), with a concentrated but comparatively young cystic-fibrosis franchise, and smaller biotechs without a Medicare-heavy blockbuster are examples of the broader pattern: exposure tracks drug age and Medicare revenue share, not company size or sector labels.

Pharmacy benefit managers — CVS Health's (CVS) Caremark, Cigna's (CI) Express Scripts, and UnitedHealth Group's (UNH) Optum Rx — sit between manufacturers and patients and have historically extracted rebates tied to list prices. A negotiated "maximum fair price" compresses the list-price rebate game for the specific drugs on the CMS list, but PBMs still control formulary placement, still negotiate rebates on every non-negotiated drug, and still run the specialty-pharmacy and mail-order businesses that are a bigger profit driver than rebate spread alone. The direct effect on PBM economics from any single year's negotiated-drug list is modest relative to their total book, but it's a mechanism worth watching as the negotiated-drug list grows every year and covers more of total Part D spend.

Separately, PBMs are under their own unrelated political pressure (FTC scrutiny, delinking rebates from list prices) that compounds with — but is distinct from — drug-price negotiation. Don't conflate the two stories: negotiation is a manufacturer-side price-setting mechanism, while PBM reform targets the middleman's rebate model. They can move the same tickers for different reasons in the same news cycle.

The tracking calendar is public and repeats annually: CMS announces the next year's selected drugs around late January or early February, publishes negotiated "maximum fair prices" the following August, and the new prices take effect on January 1 two years after selection. That means the 2028-effective list was announced in early 2026 and will have its prices published in August 2027 — the lag between selection and effective price is the window where a reader can size up which manufacturers are exposed before the market has fully priced it in.

The practical checklist: (1) pull each company's 10-K or investor day materials for revenue concentration by product; (2) check each top-selling drug's original FDA approval date against the 9-year (small molecule) or 13-year (biologic) threshold; (3) confirm whether a generic or biosimilar has already launched (which removes eligibility); (4) weight Medicare Part D/B revenue share specifically, since a drug that's mostly sold to commercially-insured or international patients has less exposure even if it's old and exclusive. This is a spreadsheet exercise, not a headline-reading exercise — the CMS drug lists and negotiated prices are published documents, not rumors.

Manufacturers have publicly cited negotiation exposure as one factor (among many, including normal patent-cliff economics) in how they think about R&D allocation, sometimes favoring drug classes or indications less likely to face early negotiation pressure. Whether this measurably shifts industry-wide R&D allocation over a full decade is still an open, debated question — but it's a mechanism worth watching in company R&D-pipeline disclosures and licensing-deal patterns, not something to assume has already happened.

A second effect is drug companies front-loading price increases and indication expansions on drugs approaching the eligibility window, since revenue captured before negotiated pricing kicks in is revenue the government can't claw back retroactively. Watching for unusual price or indication-expansion activity on a drug 1-2 years before it hits the 9-/13-year mark is a legitimate, publicly observable signal — it shows up in list-price trackers and FDA approval databases, not in any confidential document.